BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 18343072)

  • 1. Extracellular gadolinium contrast agents: differences in stability.
    Morcos SK
    Eur J Radiol; 2008 May; 66(2):175-9. PubMed ID: 18343072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK; Thomsen HS
    Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
    Kuo PH
    J Am Coll Radiol; 2008 Jan; 5(1):29-35. PubMed ID: 18180006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of thermodynamic and kinetic parameters in gadolinium chelate stability.
    Idée JM; Port M; Robic C; Medina C; Sabatou M; Corot C
    J Magn Reson Imaging; 2009 Dec; 30(6):1249-58. PubMed ID: 19938037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.
    Idée JM; Port M; Raynal I; Schaefer M; Le Greneur S; Corot C
    Fundam Clin Pharmacol; 2006 Dec; 20(6):563-76. PubMed ID: 17109649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
    Port M; Idée JM; Medina C; Robic C; Sabatou M; Corot C
    Biometals; 2008 Aug; 21(4):469-90. PubMed ID: 18344005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.
    Abraham JL; Thakral C
    Eur J Radiol; 2008 May; 66(2):200-7. PubMed ID: 18374532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):153-9. PubMed ID: 18343071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular gadolinium-based contrast media: an overview.
    Bellin MF; Van Der Molen AJ
    Eur J Radiol; 2008 May; 66(2):160-7. PubMed ID: 18358659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C.
    Frenzel T; Lengsfeld P; Schirmer H; Hütter J; Weinmann HJ
    Invest Radiol; 2008 Dec; 43(12):817-28. PubMed ID: 19002053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis.
    Thakral C; Abraham JL
    J Cutan Pathol; 2009 Dec; 36(12):1244-54. PubMed ID: 19602073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
    Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
    Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic system fibrosis: a radiologist's practical perspective.
    Martin DR
    Eur J Radiol; 2008 May; 66(2):220-4. PubMed ID: 18321672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis--implications for nephrologists.
    Saab G; Abu-Alfa A
    Eur J Radiol; 2008 May; 66(2):208-12. PubMed ID: 18342470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.